Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.

Abstract

Indoleamine 2,3-dioxygenase (IDO) exerts immunomodulatory effects due to enzymatic activities catalyzing the essential amino acid L-tryptophan. IDO activity might play an important role in regulating immune responses exerted by antigen-presenting cells as a potent tool to help escape from assault by the immune system. In this study, we performed immunohistochemical analysis for IDO expression using mouse anti-human IDO monoclonal antibody in 119 tissue samples of diffuse large B-cell lymphoma (DLBCL) obtained before treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Not only the lymphoma cells themselves but also dendritic cells (DCs) expressed IDO. Positive IDO expression in lymphoma cells was found in 38 cases (32%). Complete remission rates in patients with IDO-positive DLBCL and IDO-negative DLBCL were 55.3% and 79.0% (p=0.008), while 3-year overall survival rates were 49.8% and 78.8%, respectively (p=0.0003). IDO activity might thus play an important role in DLBCL and cells that express IDO appear important for determining outcomes after R-CHOP treatment. IDO might represent a candidate therapeutic target for DLBCL patients who show resistance to chemotherapy.

• Authors: Soranobu Ninomiya, Takeshi Hara, Hisashi Tsurumi, Masato Hoshi, Nobuhiro Kanemura, Naoe Goto, Senji Kasahara, Masahito Shimizu, Hiroyasu Ito, Kuniaki Saito, Yoshinobu Hirose, Tetsuya Yamada, Takeshi Takahashi, Mitsuru Seishima, Tsuyoshi Takami, Hisataka Moriwaki
• Journal: Annals of hematology (Ann Hematol) Vol. 90 Issue 4 Pg. 409-16 (Apr 2011) ISSN: 1432-0584 [Electronic] Germany
• PMID: 20938662 (Publication Type: Journal Article, Randomized Controlled Trial)

Chemical References

• Antibodies, Monoclonal
• Antineoplastic Agents
• Biomarkers, Tumor
• Indoleamine-Pyrrole 2,3,-Dioxygenase
• Vincristine
• Doxorubicin
• Cyclophosphamide
• Prednisone

Topics

• Adult
• Aged
• Aged, 80 and over
• Animals
• Antibodies, Monoclonal (metabolism)
• Antineoplastic Agents (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Biomarkers, Tumor (metabolism)
• Cyclophosphamide (therapeutic use)
• Doxorubicin (therapeutic use)
• Female
• Humans
• Indoleamine-Pyrrole 2,3,-Dioxygenase (metabolism)
• Lymphoma, Large B-Cell, Diffuse (diagnosis, drug therapy, enzymology, pathology)
• Male
• Mice
• Middle Aged
• Prednisone (therapeutic use)
• Prognosis
• Remission Induction
• Retrospective Studies
• Treatment Outcome
• Vincristine (therapeutic use)
• Young Adult